Aeglea BioTherapeutics Operating Income

Aeglea BioTherapeutics (AGLE) currently reports a operating income of $-200M as of June 2026. That compares with $-160M in the prior-year period — down 23.5% year over year. Use the charts on this page to explore Aeglea BioTherapeutics's operating income history and peer comparisons.

Aeglea BioTherapeutics's operating income decreased from $-160M to $-200M — a 23.5% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Aeglea BioTherapeutics reported $-200M in operating income as of June 2026. That compares with $-160M in the prior-year period — down 23.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-200M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Aeglea BioTherapeutics, and consider following AGLE for alerts when major investors trade the stock.

Aeglea BioTherapeutics is classified in the Healthcare sector. On operating income, it currently shows $-200M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AGLE with unrelated industries.